Hyderabad, India, October 27, 2025: Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India’s fastest growing Contract […]
Global Business Reports interviews Krishna Kanumuri, MD & CEO Sai Life Sciences on the company’s journey of transformation
3 Dec 2019
A recent edition of Global Business Reports (GBR) on India Pharmaceuticals 2019 features the interview with Krishna Kanumuri, MD & CEO of Sai Life Sciences. In the interview, Krishna provides a glimpse of the 20 years of the company, and how it is building itself for the future.
Here’s an excerpt from the interview:
“Sai Life Sciences is undergoing major transformation. Over a period from 2016 to 2020, our company is quadrupling in capacity. This capacity, combined with our proven track record and commitment to building long term partnerships, will no doubt make Sai Life Sciences the partner of choice for large pharma and small biotechs in bringing new medicines to life.”, says CEO Krishna Kanumuri.
Here is the link to read the full interview.
Related News
Manchester/Hyderabad, October 08, 2025: Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), Agility Life Sciences, and Centrix Pharma Solutions today […]
8 Oct 2025
As part of Sai Life Sciences’ efforts to foster knowledge exchange and bring leading voices from niche areas of science […]